Episode Synopsis "HER2-Directed ADCs in Breast Cancer "

Guest: Sara A. Hurvitz, MD, FACP

Listen "HER2-Directed ADCs in Breast Cancer "

More episodes of the podcast Global Oncology Academy

• ATTR Amyloidosis: Familial Vs Wild-Type
• ATTRv-PN: A Complicated Disease With a Poor Prognosis
• The Multiple Faces of ATTRv-PN
• Raising the Red Flag: What's Your Index of Suspicion for ATTRv-PN?
• Diagnosing ATTRv-PN: What's in Your Toolbox?
• Shh…Gene-Silencing Therapies for ATTRv-PN
• ATTRv-PN: A Family Affair?
• Advancing the Treatment of ATTRv-PN: What's in the Pipeline?
• Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review
• A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events
• Clinical Challenges With Triple-Class or Penta-Refractory MM
• Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
• The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies
• Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials
• Efficacy Data for Bispecific Antibodies in RRMM
• Preventing CRS and Neurotoxicities Related to Bispecific Antibodies
• Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies
• Considerations for Dosing Bispecific Antibodies
• Step-Up Dosing of Bispecific Antibodies: The Need for Hospitalization
• Integrating Bispecific Antibodies Into Clinical Practice
• Balancing the Scales: The Complementary Roles of RCTs and RWE in Modern Healthcare
• Distinguishing Between High- and Low-Quality RWE: A Journal Club for the Real World
• RWE Supporting CDK4/6 Inhibitor Use in HR+ Metastatic Breast Cancer
• Unlocking Insights for Underrepresented Patients: The Role of Real-World Evidence in Addressing Limitations of CDK4/6 Inhibitor RCTs
• Importance of the Patient Perspective on RWE in Formulating SDM Conversations
• Real World Use of RWE in HR+ Metastatic Breast Cancer: The Oncologist Perspective
• Real World Evidence To Expand Knowledge of CDK4/6 Inhibitor-Related Adverse Effects
• Revolutionary Approaches to Improving Outcomes in Unresected LA SCCHN
• Keeping Pace in Hematologic Malignancies: 2023 Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes
• HER2-Directed ADCs in Breast Cancer